Login to Your Account

Blend lands $38M series C, remaps course with new lead, name change

By Michael Fitzhugh
Staff Writer

Wednesday, January 27, 2016

Blend Therapeutics Inc. said it will use a $38 million series C equity financing to carry a new lead candidate for neuroendocrine cancers into phase I studies by mid-year and what president and CEO Drew Fromkin told BioWorld Today will be "well through major data inflection points."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription